These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25676691)

  • 1. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
    Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
    Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CXCR4-dependent immunosuppressive Ly6C
    Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
    Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS
    Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
    Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
    Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
    Momeny M; Shamsaiegahkani S; Kashani B; Hamzehlou S; Esmaeili F; Yousefi H; Irani S; Mousavi SA; Ghaffari SH
    Life Sci; 2021 Dec; 287():120100. PubMed ID: 34715143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
    Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J
    Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
    Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
    J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.
    Rubin JB; Kung AL; Klein RS; Chan JA; Sun Y; Schmidt K; Kieran MW; Luster AD; Segal RA
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13513-8. PubMed ID: 14595012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
    Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
    Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
    Becker MA; Farzan T; Harrington SC; Krempski JW; Weroha SJ; Hou X; Kalli KR; Wong TW; Haluska P
    Mol Cancer Ther; 2013 Dec; 12(12):2909-16. PubMed ID: 24130056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
    Peterson TE; Kirkpatrick ND; Huang Y; Farrar CT; Marijt KA; Kloepper J; Datta M; Amoozgar Z; Seano G; Jung K; Kamoun WS; Vardam T; Snuderl M; Goveia J; Chatterjee S; Batista A; Muzikansky A; Leow CC; Xu L; Batchelor TT; Duda DG; Fukumura D; Jain RK
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4470-5. PubMed ID: 27044097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
    J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.
    Gatti M; Pattarozzi A; Bajetto A; Würth R; Daga A; Fiaschi P; Zona G; Florio T; Barbieri F
    Toxicology; 2013 Dec; 314(2-3):209-20. PubMed ID: 24157575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.